Paliperidone Palmitate

A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.

Also Known As:

3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 9-Hydroxy-risperidone; 9-Hydroxyrisperidone; 9-OH-risperidone; Invega; Invega Sustenna; Paliperidone; R 76477; R-76477; 9 Hydroxy risperidone; 9 Hydroxyrisperidone; 9 OH risperidone; Palmitate, Paliperidone; R76477; Sustenna, Invega

Networked: 924 relevant articles (129 outcomes, 329 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Isoxazoles: 155
      - Paliperidone Palmitate: 924
        isoperidone: 1
  - Pyrimidines: 510
    - Paliperidone Palmitate: 924
      - isoperidone: 1

Experts

1.	Gopal, Srihari: 59 articles (01/2022 - 08/2009)
2.	Alphs, Larry: 41 articles (01/2022 - 12/2009)
3.	Nuamah, Isaac: 35 articles (01/2021 - 01/2011)
4.	Hough, David: 35 articles (06/2020 - 05/2008)
5.	Turkoz, Ibrahim: 33 articles (01/2022 - 07/2008)
6.	Mathews, Maju: 25 articles (01/2021 - 10/2016)
7.	Bossie, Cynthia A: 24 articles (04/2017 - 07/2008)
8.	Fu, Dong-Jing: 23 articles (01/2022 - 05/2011)
9.	Lefebvre, Patrick: 20 articles (01/2021 - 03/2015)
10.	Joshi, Kruti: 19 articles (01/2021 - 11/2016)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 05/28/2012 - "Intramuscular paliperidone palmitate 25-150 mg equivalents (mg eq.) effectively reduced symptoms of schizophrenia in most short-term (9-13 weeks) placebo-controlled trials, as demonstrated by improvements in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to endpoint that were significantly greater in intramuscular paliperidone palmitate than placebo recipients. " 10/26/2021 - "Paliperidone 3-monthly (PP3M) long-acting injection has proven efficacy and effectiveness in schizophrenia. " 08/01/2015 - "The present study demonstrates that flexible dose of paliperidone resulted in a significant improvement in functioning and reduction in symptoms in patients with recent onset schizophrenia." 07/09/2010 - "Paliperidone ER 3-12 mg/day improved Positive and Negative Syndrome Scale (PANSS) total scores (primary endpoint) from baseline to study end to a significantly greater extent than placebo in 6-week, double-blind trials in patients with acute symptoms of schizophrenia. " 07/01/2007 - "In this study, all doses of paliperidone ER were effective in significantly improving the symptoms of schizophrenia and personal and social functioning and were generally well tolerated. "
2.	Psychotic Disorders (Schizoaffective Disorder) 01/01/2018 - "Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder." 11/01/2015 - "This analysis evaluates improvement in symptoms of depression in patients with schizoaffective disorder administered oral paliperidone extended-release by accounting for the magnitude of direct and indirect (changes in negative and positive symptoms and worsening of extrapyramidal symptoms) treatment effects on depressive symptoms. " 01/01/2023 - "Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis-A Retrospective Mirror-Image Study." 05/01/2018 - "This case suggests that paliperidone palmitate may be efficacious for psychosis following TBI; however, further study is warranted." 08/01/2017 - "Areas covered: We reviewed the literature using keywords 'paliperidone', 'schizoaffective disorder' and 'clinical trials' with a focus on seminal data papers and information that is clinically relevant to the treatment of schizoaffective disorder. "
3.	Mania (Manias) 10/01/2017 - "Our preliminary results suggest that paliperidone does not offer significant benefits for the treatment of mania symptoms in BD compared with a placebo. " 10/01/2010 - "Subjects with prominent manic or depressive symptoms showed greater improvement with paliperidone ER versus placebo: mean (SE) Young Mania Rating Scale (-10.6 [0.9] vs -5.7 [1.2], respectively) and 21-item Hamilton Rating Scale for Depression (-10.2 [0.7] vs -6.2 [1.1], respectively). " 06/01/2013 - "This study evaluates the safety and efficacy of paliperidone monotherapy as an acute treatment of mania and related symptoms in youth with bipolar spectrum disorders. " 05/01/2012 - "Paliperidone ER monotherapy was efficacious in treating acute mania in two 3-week studies in patients with bipolar I disorder. " 01/01/2012 - "A literature search was performed from January 1966 through January 2012 using PreMEDLINE, MEDLINE, EMBASE, IPA, and ClinicalTrials.gov to identify articles in English regarding the pharmacology, clinical efficacy, and safety of paliperidone ER in acute mania or mixed episodes or in the maintenance treatment of BD I. There are currently three published studies relating to the use of paliperidone ER for the treatment of BD. "
4.	Treatment-Resistant Schizophrenia 07/01/2022 - "However, few studies have explored the efficacy of paliperidone for treatment-resistant schizophrenia. " 07/01/2022 - "Paliperidone ER could be a safe alternative for treatment-resistant schizophrenia." 10/01/2022 - "Successful treatment using combined monthly maintenance electroconvulsive therapy and monthly long-acting injection paliperidone for treatment-resistant schizophrenia with vulnerability to clozapine: A case report." 07/01/2022 - "Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study." 01/01/2020 - "We describe the case of a 49-year-old Japanese male patient successfully treated with a paliperidone rechallenge following 2-year treatment with clozapine for treatment-resistant schizophrenia. "
5.	Sleep Initiation and Maintenance Disorders (Insomnia) 09/01/2007 - "Paliperidone extended-release was well tolerated and improved sleep architecture and sleep continuity in patients diagnosed with schizophrenia and concomitant insomnia." 02/01/2008 - "Headache and insomnia were the most common adverse events in patients treated with paliperidone ER in the 6-week trials (pooled data: 11%-18% and 4%-14%, respectively). " 09/01/2007 - "The effects of paliperidone extended-release on sleep architecture in patients with schizophrenia-related insomnia were evaluated in this multicenter, double-blind, randomized, placebo-controlled study. " 08/01/2015 - "Paliperidone ER was generally well tolerated, with frequently reported treatment-emergent adverse events being insomnia, anxiety and somnolence. " 10/01/2011 - "Most common AEs (≥10%) in any paliperidone palmitate group were insomnia, anxiety, and headache. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Risperidone (Risperdal Consta)
3.	Aripiprazole (Abilify)
4.	Olanzapine (Zyprexa)
5.	Clozapine (Clozaril)
6.	Paliperidone Palmitate
7.	Tablets
8.	Quetiapine Fumarate (Seroquel)
9.	ziprasidone (Geodon)
10.	Haloperidol (Haldol)

Related Therapies and Procedures

1.	Injections
2.	Therapeutics
3.	Intramuscular Injections
4.	Secondary Prevention
5.	Patient Readmission